Pneumonia severity index: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Chris Day
Line 12: Line 12:
==References==
==References==
<references/>
<references/>
==External links==
*[http://pda.ahrq.gov/clinic/psi/psicalc.asp Pneumonia Severity Index Calculator]
[[Category:Pneumonia]]

Revision as of 15:54, 8 January 2009

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

The pneumonia severity index (PSI) is a clinical prediction rule to estimate the probability of complications among patients with community acquired pneumonia.[1]

The accuracy of the PSI has been independently validated by other researchers.[2]

Patients with PSI Risk groups I-III can usually be treated as an outpatient.[3]

A randomized controlled trial found that use of the PSI to guide management of community acquired pneumonia improved medical care by reducing resource consumption without reducing quality of care.[4]

The pneumonia severity index has been compared to the CURB-65 in predicting mortality.[2]

References

  1. Fine MJ, Auble TE, Yealy DM, et al (1997). "A prediction rule to identify low-risk patients with community-acquired pneumonia". N. Engl. J. Med. 336 (4): 243–50. PMID 8995086[e]
  2. 2.0 2.1 Aujesky D, Auble TE, Yealy DM, et al (2005). "Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia". Am. J. Med. 118 (4): 384-92. DOI:10.1016/j.amjmed.2005.01.006. PMID 15808136. Research Blogging.
  3. Carratalà J, Fernández-Sabé N, Ortega L, et al (February 2005). "Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients". Ann. Intern. Med. 142 (3): 165–72. PMID 15684204[e]
  4. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG (2000). "A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin". JAMA 283 (6): 749-55. PMID 10683053[e]